Insmed Incorporated (NASDAQ:INSM) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Insmed Incorporated (NASDAQ:INSM) have been given a consensus rating of “Buy” by the sixteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Sixteen investment analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $94.00.

Several research analysts have commented on INSM shares. Morgan Stanley lifted their price target on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Guggenheim reiterated a “buy” rating and set a $101.00 target price on shares of Insmed in a research note on Tuesday, February 25th. JPMorgan Chase & Co. raised their price target on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Stifel Nicolaus cut their price objective on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th.

Insmed Price Performance

Shares of Insmed stock opened at $77.99 on Friday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The firm has a fifty day simple moving average of $78.18 and a 200-day simple moving average of $73.99. The stock has a market capitalization of $14.12 billion, a price-to-earnings ratio of -13.95 and a beta of 1.28. Insmed has a 1-year low of $21.92 and a 1-year high of $84.91.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. On average, sell-side analysts expect that Insmed will post -4.56 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Sara Bonstein sold 3,470 shares of Insmed stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $65.70, for a total value of $227,979.00. Following the completion of the transaction, the chief financial officer now directly owns 114,736 shares of the company’s stock, valued at $7,538,155.20. The trade was a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the sale, the chief executive officer now directly owns 384,960 shares in the company, valued at approximately $26,885,606.40. This represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 550,957 shares of company stock worth $42,992,528 in the last quarter. 4.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Insmed

Large investors have recently modified their holdings of the stock. Elequin Capital LP acquired a new stake in shares of Insmed in the fourth quarter valued at approximately $28,000. Steward Partners Investment Advisory LLC boosted its position in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 163 shares during the last quarter. V Square Quantitative Management LLC increased its stake in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 248 shares during the period. Spire Wealth Management bought a new stake in shares of Insmed during the fourth quarter worth $47,000. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 411 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.